Time for the #AACR25 Annual Reception, featuring the #Checkpoints! Be there tonight 830 PM at McCormick Place West (Level 3) in the Skyline Ballroom (W375). We have a bunch of new tunes & rehearsal was great! @theaacr.bsky.social
Podcast alert! Enjoyed discussing #ASCO25 #Immunotherapy & #Melanoma data w Dr. Diwakar Davar. Important studies that are advancing the field! @ascocancer.bsky.social
dailynews.ascopubs.org/do/podcast-i...
The CheckPoints are ready to party - join us tonight Sunday June 1 at Buddy Guys! Best party of #ASCO25 & all for the great cause of the @sitcancer.bsky.social Forward Fund that supports post-doc & trainee awards. See you tonight!!!
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
A @sitcancer.bsky.social vision statement on accelerating #clinicaltrials to get 100 immunotherapy regulatory approvals in 10 years. Excited to be part of this effort for the paper, for our field but most importantly for the people with #cancer we are working to #cure!
jitc.bmj.com/content/13/3...
Excited to help lead Phase 2/3 frontline metastatic #melanoma TeLuRide-006 study of pembro +/- novel IV TLR7/8 agonist EIK1001. Super interesting pre-clinical & prelim responses in PD1 refractory dz. Trial is open in #Pittsburgh & globally for accrual!
clinicaltrials.gov/study/NCT066...
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
VIP tickets are available now! The CheckPoints will be back in Chicago on June 1 at Buddy Guy’s Legends. Donations will support SITC’s Forward Fund and benefit the next generation of cancer immunotherapy experts. LEARN MORE: www.sitcancer.org/funding/the-... #RockinForACure
Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @natmedicine.bsky.social! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx.
www.nature.com/articles/s41...
Appreciate the profile www.statnews.com/pharmalot/20... from Ed Silverman & @statnews.com! Amazing progress at Strand Therapeutics advancing field leading genetic medicines. Check my quote on being a nutating mixer if I were a piece of lab equipment ;)
#synbio #immunotherapy #cancerresearch
Talking IMA203 & SUPRAME trial #iwCART25 in Miami last wknd. Pass the word to #melanoma patients needing novel therapeutics. After ICI, this therapy has possibility for long-term dz control! Trial opening in USA & Europe. 1st pt got IMA203 in Pittsburgh last week!
clinicaltrials.gov/study/NCT067...
